+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

Cost of 651 essential medicines down 7% from April, as govt caps ceiling prices

Apr 3, 2023, 15:29 IST
PTI
Pexels
Cost of 651 essential medicines has come down by an average of 6.73 per cent from April with the government capping ceiling prices of a majority of the scheduled drugs, NPPA said on Monday. In a tweet, the national drug price regulator said the government has been able to fix the ceiling prices of 651 medicines so far out of the total 870 scheduled drugs listed under National List of Essential Medicines (NLEM).
Advertisement

The health ministry had amended NLEM in September 2022 and it now has a total of 870 drugs.

The National Pharmaceutical Pricing Authority (NPPA) noted that with the capping of ceiling prices, the cost of 651 essential drugs on an average had already come down by 16.62 per cent.

"Due to this, the price of 651 essential drugs, which was to go up by 12.12 per cent, has actually come down by 6.73 per cent from April 1," NPPA said.

Consumers will benefit from this decline in prices despite a 12.12 per cent annual hike in prices of drugs based on WPI, it added.

Advertisement

Annual hikes in prices of drugs listed in NLEM are based on WPI.

In a statement dated March 25, NPPA had stated that the annual change in Wholesale Price Index (WPI) was 12.12 per cent for 2022.

NPPA fixes the ceiling price of essential medicines of Schedule I under the Drugs (Prices Control) Order (DPCO) 2013.

The calculation for essential drugs is based on the simple average of all the medicines in a particular therapeutic segment with sales of more than 1 per cent.

You are subscribed to notifications!
Looks like you've blocked notifications!
Next Article